10X Technologies

10X Technologies is a biotechnology company specializing in advanced genomic technologies to enhance understanding of biological systems and support human health innovations. Their products empower researchers in genomics and biomedical fields. 10X Technologies, founded in 2012 by Ben Hindson and Serge Saxonov, operates from Oakland, US. The company has raised a total of USD 0.

55 mn through funding rounds, including the Series B round in January 2015. Their business focuses on developing innovative genomic solutions without a noted change in operational strategy or structure. 10X Technologies specializes in advanced genomic technologies that facilitate a deeper understanding of biological systems and advance human health. The company's core product offerings include platforms such as Chromium Single Cell, Visium Spatial, and Xenium In Situ, each designed to measure and analyze gene expression at a single-cell resolution.

These platforms enable researchers to conduct comprehensive transcriptomic profiling, perform whole transcriptome analysis in the context of tissue morphology, and map RNA molecules with high spatial resolution. The end users of these products primarily consist of academic and industrial researchers in fields such as genomics, pharmaceutical development, and biomedical research. Geographically, 10X Technologies markets its products globally, with significant penetration in North America, Europe, and Asia, catering to a diverse clientele of institutions and laboratories engaged in cutting-edge research. 10X Technologies generates revenue through a combination of direct sales and partnerships with research institutions and companies involved in life sciences.

The company's transactions typically involve the sale of its flagship products, including the Chromium Single Cell platform and Visium Spatial technology, which are offered at established pricing structures based on product specifications and customer needs. The company engages primarily in B2B transactions, supplying these advanced genomic tools to laboratories and research facilities rather than retail consumers. This transactional model allows 10X Technologies to maintain strong relationships with its clientele, facilitating repeat business and ongoing collaborations in innovative research projects. 10X Technologies aims to enhance its market presence by introducing new products and expanding into diverse geographic regions.

The recent funding of USD 0. 55 mn from the Series B round in January 2015 will support the development of innovative genomic technologies. The company is looking to penetrate new markets in Asia and Europe, with plans to launch additional products within the next 12 to 18 months, thereby addressing the growing demand in the life sciences sector.